Skip to main
ELVN

ELVN Stock Forecast & Price Target

ELVN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enliven Therapeutics is strategically focusing its resources on the development of promising therapeutics, specifically the HER3-targeting ADC, EO-1022, which positions the company to capitalize on opportunities within the evolving biotechnology sector. The management's decision to execute a workforce reduction reflects a commitment to financial prudence, aiming to streamline operations amid a challenging financial environment. Despite recent adjustments to revenue projections and an increase in the discount rate, the long-term potential of ELVN-001 and ELVN-002 underscores a positive outlook for the company's growth trajectory in treating significant oncogenic drivers in oncology.

Bears say

Enliven Therapeutics recently decided to discontinue the development of its Claudin 18.2-targeting ADC, EO-3021, due to disappointing efficacy results in its ongoing Phase 1 study. Although the drug has demonstrated tolerability, its low efficacy raises concerns regarding its viability as an independent therapeutic option and diminishes prospects for future investment. Consequently, this combination of halted drug development and reduced expectations reflects a challenging outlook for Enliven Therapeutics's financial position and future growth potential.

ELVN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enliven Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enliven Therapeutics Inc (ELVN) Forecast

Analysts have given ELVN a Strong Buy based on their latest research and market trends.

According to 4 analysts, ELVN has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enliven Therapeutics Inc (ELVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.